Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting

W. Simons

PharmacoEconomics, 2003, vol. 21, issue 1, 74 pages

Abstract: Objective: To compare the cost effectiveness of the angiotensin II receptor blockers (ARBs) olmesartan medoxomil, losartan, valsartan and irbesartan for the treatment of hypertension, from the perspective of a US managed care setting. Methods: The evaluation was based on a recently completed, prospective, randomised, double-blind clinical trial comparing the antihypertensive efficacy of these agents. Differences in diastolic blood pressure reductions among the comparative agents were used to estimate reductions in the annualised risk of cardiovascular (CV) and cerebrovascular events using the Framingham model. These annualised risks were translated into reductions in healthcare expenditures associated with treating CV events covered by managed care in the US. Data sources included: the recently published clinical trial of ARB antihypertensive efficacy, the Framingham Heart Study and a managed care database. Actual reimbursed amounts were used. Results: Based on antihypertensive efficacy data versus irbesartan, the use of olmesartan medoxomil is expected to reduce the number of new cases of CV disease, resulting in a first-year reduction in cost in a cohort of 100 000 patients of $US906 000. Similarly, a reduction in new cases of coronary heart disease (CHD) resulted in a cost reduction of $US701 000; a cost reduction of $US196 000 for fewer myocardial infarctions (MI); and a cost reduction of $US28 000 for fewer strokes. Over 5 years, these estimates increase to $US5 410 000 for fewer cases of CV disease; $US3 975 000 for fewer cases of CHD; $US1 430 000 for fewer MI; and $US497 000 for fewer strokes. Compared with valsartan, the use of olmesartan medoxomil is estimated to reduce by $US3 397 000 the expected cost of treating a cohort of 100 000 patients in the first year for fewer cases of CV disease; by $US2 426 000 for fewer cases of CHD; by $US565 000 for fewer MI; and by $US124 000 for fewer strokes. Over 5 years, these estimates increase to $US16 231 000 for CV disease; $US11 955 000 for CHD; $US4 505 000 for MI; and $1 741 000 for stroke. Compared with losartan, the estimated reduction in first-year cost is $US2 969 000 for CV disease for the cohort of 100 000 patients; $US2 163 000 for CHD; $US732 000 for MI; and $US124 000 for stroke. Over 5 years, these estimates increase to $US15 149 000 for CV disease; $US11 107 000 for CHD; $US4 057 000 for MI; and $1 437 000 for stroke. Conclusion: Based on comparative antihypertensive efficacy data, treatment of hypertensive patients with olmesartan medoxomil instead of the other leading ARBs has the potential to reduce overall cost of medical care in a US managed care setting. Copyright Adis International Limited 2003

Date: 2003
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200321010-00005 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:21:y:2003:i:1:p:61-74

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200321010-00005

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().